The tumor microenvironment in tumorigenesis and therapy resistance revisited
Simple Summary Tumors are not masses of cancer cells alone but made up of cancer cells,
other cells including fibroblasts, macrophages, endothelial cells, as well as secreted factors …
other cells including fibroblasts, macrophages, endothelial cells, as well as secreted factors …
Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations
R Salani, FJ Backes, MFK Fung… - American journal of …, 2011 - Elsevier
Although gynecologic cancers account for only 10% of all new cancer cases in women,
these cancers account for 20% of all female cancer survivors. Improvements in cancer care …
these cancers account for 20% of all female cancer survivors. Improvements in cancer care …
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
J Pfisterer, CM Shannon, K Baumann, J Rau… - The Lancet …, 2020 - thelancet.com
Background State-of-the art therapy for recurrent ovarian cancer suitable for platinum-based
re-treatment includes bevacizumab-containing combinations (eg, bevacizumab combined …
re-treatment includes bevacizumab-containing combinations (eg, bevacizumab combined …
Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study
CY Lan, Y Wang, Y Xiong, JD Li, JX Shen, YF Li… - The Lancet …, 2018 - thelancet.com
Background Anti-angiogenic therapy combined with chemotherapy could improve the
outcomes of patients with platinum-resistant ovarian cancer. Apatinib is an oral tyrosine …
outcomes of patients with platinum-resistant ovarian cancer. Apatinib is an oral tyrosine …
Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas
D Etemadmoghadam, A Defazio, R Beroukhim… - Clinical cancer …, 2009 - AACR
Purpose: A significant number of women with serous ovarian cancer are intrinsically
refractory to platinum-based treatment. We analyzed somatic DNA copy number variation …
refractory to platinum-based treatment. We analyzed somatic DNA copy number variation …
[HTML][HTML] Practical strategy to construct anti-osteosarcoma bone substitutes by loading cisplatin into 3D-printed titanium alloy implants using a thermosensitive hydrogel
Z Jing, R Ni, J Wang, X Lin, D Fan, Q Wei, T Zhang… - Bioactive Materials, 2021 - Elsevier
Surgical resection and perioperative adjuvant chemotherapy-based therapies have
improved the prognosis of patients with osteosarcoma; however, intraoperative bone …
improved the prognosis of patients with osteosarcoma; however, intraoperative bone …
HE4: a new potential early biomarker for the recurrence of ovarian cancer
E Anastasi, G Giovanna Marchei, V Viggiani… - Tumor Biology, 2010 - Springer
Abstract Human epididymis protein 4 (HE4) has recently been described as a new marker
for the early diagnosis of ovarian cancer (OC). The objective of this study was to evaluate (a) …
for the early diagnosis of ovarian cancer (OC). The objective of this study was to evaluate (a) …
Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments
M Kyrgiou, G Salanti, N Pavlidis… - Journal of the …, 2006 - academic.oup.com
Background: Numerous randomized trials have compared different chemotherapy regimens
in women with ovarian cancer. Although ovarian cancer survival has improved in recent …
in women with ovarian cancer. Although ovarian cancer survival has improved in recent …
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome
Purpose: High-grade serous cancer (HGSC) is the most common cancer of the ovary and is
characterized by chromosomal instability. Defects in homologous recombination repair …
characterized by chromosomal instability. Defects in homologous recombination repair …
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or …
C Lhommé, F Joly, JL Walker, AA Lissoni… - Journal of clinical …, 2008 - ascopubs.org
Purpose To compare the safety and efficacy of carboplatin and paclitaxel administered with
or without the multidrug resistance modulator valspodar (PSC 833) in untreated patients with …
or without the multidrug resistance modulator valspodar (PSC 833) in untreated patients with …